| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Canadian Journal of Anesthesia, Vol 6, 375-384, Copyright © 1959 by Canadian Anesthesiologists' Society
1 Section of Anaesthesiology, Department of Surgery, University of Kansas Medical Center, Kansas City, Kan
Tranquillizing drugs are of great interest to anaesthesiologists. The investigation of new compounds continues in the hope of finding even more satisfactory agents.
The pharmacology of triflupromazine is briefly reviewed and also the clinical findings of other investigators.
This report deals with the clinical findings after giving triflupromazine to 1,577 patients (postoperatively, 30; pre-anaesthetic—local 655, general 725, spinal 167).
Favourable effects including good psychic sedation without mental elouding; significant decrease in postoperative nausea and vomiting; moderate potentiation of narcotics; slight potentiation of barbiturates, minimal potentiation of anaesthetic agents; no respiratory depression or evidence of toxicity to the renal, hepatic or haemopoietic systems.
Better sedation is attained by combination with small amounts of meperidine and/or pentobarbital. Side-effects are minimal if dosage of all agents is chosen with care. Such combinations are considered very satisfactory prior to local analgesia.
Though some hypotension was seen, its incidence and severity can be minimized by careful selection of dosage.
Further investigation of this agent is considered desirable.
Note:
Vesprin® is the trade name of triflupromazine Squibb.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |